Business
The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions
CONCORD, Calif., August 25, 2025--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transfu
About this update from Cerus Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/26a272d94d7e9e7a8648aa2559acd938"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l.r2JHXlBvT.pwlZGl10gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/26a272d94d7e9e7a8648aa2559acd938","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/p5O0HAJz5DGwaDp6bGTpbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/26a272d94d7e9e7a8648aa2559acd938","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CONCORD, Calif., August 25, 2025--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transfusion.","length":522,"tagName":"p"},{"type":"text","content":""We believe today’s recommendation from AK Blut affirms the critical role of pathogen inactivation in protecting patients from transfusion-transmitted bacterial infections. Enhancing patient safety is clearly a key priority of AK Blut and blood centers around the world and the INTERCEPT Blood System has an extensive track record of over 20 million blood components treated globally," said Christian Boutemy, Cerus’ vice president of international commercial operations. "Over 600,000 platelet doses are produced annually in Germany, more than any other European country, and we look forward to collaborating with German blood banks and hospitals to enhance the safety and reliability of the platelet supply. INTERCEPT Blood System for Platelets is approved and commercially available in Germany."","length":818,"tagName":"p"},{"type":"text","content":"The report, Enhancing the Bacteriological Safety of Platelet Concentrates, highlights that while existing safeguards have reduced the risk of transfusion-transmitted bacteria...